Saturday 17 October 2026
Export SRTS’s income statement to Excel — free account
Sensus Healthcare, Inc.
SRTS Healthcare Medical Devices
Sensus Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, down 34.3% from fiscal 2024. In the quarter to June 2026, revenue fell 68.7%, EPS fell 783.3% and free cash flow fell 201.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.77
0.00
0.00%
Follow SRTS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.84 | 2.91 | 2.36 | 1.44 | |
P/FCF ratio |
0.00 | 0.00 | 195.73 | 23.65 | |
P/Operating CF |
(15.87) | (17.46) | (29.44) | 22.33 | |
P/B ratio |
1.35 | 1.44 | 1.35 | 1.00 | |
Price to Tangible BV |
1.35 | 1.44 | 1.35 | 1.00 | |
EV/Sales |
2.31 | 2.35 | 1.77 | 0.92 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.94) | (96.78) | 92.31 | 17.10 | |
EV/FCF |
(5.79) | (71.67) | 146.81 | 15.06 | |
Quick Ratio |
3.90 | 3.74 | 5.96 | 4.97 | |
Current Ratio |
8.71 | 7.27 | 9.72 | 7.38 | |
Net Debt/EBITDA |
5.01 | 4.36 | 7.40 | 10.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.35 | 0.40 | 0.48 | 0.60 | |
Operating CF/Net income |
0.36 | 1.43 | 0.70 | (2.43) | |
Capex/Depreciation |
(0.05) | (0.02) | (0.96) | (0.03) | |
Research and Development Expense of Revenue |
48.43% | 46.85% | 38.10% | 26.42% | |
Selling, General and Administrative Expense of Revenue |
124.02% | 110.75% | 64.06% | 50.31% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.06% | 2.06% | 1.54% | 1.06% | |
Graham Net Nets |
0.67 | 0.56 | 0.63 | 0.84 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(31.13%) | (11.81%) | (11.81%) | (6.05%) | |
Free Cash Flow Yield |
(14.02%) | (1.13%) | 0.51% | 4.23% | |
Revenue per Share |
0.14 | 0.21 | 0.30 | 0.42 | |
Operating CF per Share |
(0.19) | (0.23) | (0.14) | 0.14 | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.19) | (0.23) | (0.14) | 0.14 | |
Cash per Share |
0.92 | 1.11 | 1.35 | 1.50 | |
Shareholders Equity per Share |
2.24 | 2.77 | 2.95 | 3.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.24 | 2.77 | 2.95 | 3.14 | |
Free Cash Flow |
(3.14) | (3.76) | (2.36) | 2.29 | |
Working Capital |
33.35 | 36.73 | 41.17 | 43.40 | |
Capital Expenditures |
(0.01) | 0.00 | (0.16) | 0.00 | |
Net Current Asset Value |
33.28 | 36.59 | 40.95 | 43.10 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.15 | 10.80 | 12.89 | 13.15 | |
Average Payables |
4.27 | 5.16 | 4.08 | 4.80 | |
Average Inventory |
17.08 | 17.28 | 14.76 | 14.04 | |
Average Assets |
50.06 | 55.88 | 57.60 | 59.08 | |
Average Common Equity |
44.46 | 49.29 | 51.96 | 52.66 |
Columns are period end dates